No Data
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA
Express News | Neumora Therapeutics Inc: Expects to Report Topline Data From Phase 1B Study in Second Half of 2025
Express News | Neumora Therapeutics Announces Initiation of Phase 1B Study of Nmra-511 for Treatment of Alzheimer’s Disease Agitation
Neumora Therapeutics (NASDAQ:NMRA) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares sinc
RBC Capital Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $29
RBC Capital analyst Brian Abrahams maintains $Neumora Therapeutics(NMRA.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 49.4
BofA Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $22
BofA Securities analyst Geoff Meacham maintains $Neumora Therapeutics(NMRA.US)$ with a buy rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 4